Literature DB >> 12009495

Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid.

C E Teunissen1, J de Vente, H W M Steinbusch, C De Bruijn.   

Abstract

The diagnosis of Alzheimer's disease (AD) is currently based on clinical and neuropsychological examination. To date there is no blood test available that can discriminate dementia patients from healthy individuals. In the present paper, an overview of the current state of knowledge on biologic markers in serum (plasma) and CSF is presented. The combination of characteristic plaque markers tau and amyloid bèta may constitute a specific and sensitive CSF marker for AD. Glial fibrillary acidic protein and antibodies in CSF may be a marker for severe neurodegeneration. CSF concentrations of the oxidative stress markers 3-nitrotyrosine, 8-hydroxy-2'-deoxyguanosine and isoprostanes are increased in AD patients. Serum 24S-OH-cholesterol may be an early whereas glial fibrillary acidic protein autoantibody level may be a late marker for neurodegeneration. To date, serum alpha(1)-Antichymotripsin concentration is the most convincing marker for CNS inflammation. Increased serum homocysteine concentrations have also been consistently reported in AD. In summary, a large overlap in mean concentrations has been observed in studies comparing AD patients with healthy controls for single markers. These studies together support the theory of testing several serum markers in combination for the diagnosis of AD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12009495     DOI: 10.1016/s0197-4580(01)00328-1

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  35 in total

Review 1.  Oxidative stress in phenylketonuria: what is the evidence?

Authors:  Graziela S Ribas; Angela Sitta; Moacir Wajner; Carmen R Vargas
Journal:  Cell Mol Neurobiol       Date:  2011-04-23       Impact factor: 5.046

Review 2.  Biomarkers of Alzheimer disease in plasma.

Authors:  Michael C Irizarry
Journal:  NeuroRx       Date:  2004-04

Review 3.  Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood.

Authors:  Anders Lönneborg
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 4.  Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.

Authors:  Carmen Noelker; Harald Hampel; Richard Dodel
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

5.  Biomarkers of Alzheimer's disease among Mexican Americans.

Authors:  Sid E O'Bryant; Guanghua Xiao; Melissa Edwards; Michael Devous; Veer Bala Gupta; Ralph Martins; Fan Zhang; Robert Barber
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

6.  Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Authors:  Susanne G Mueller; Michael W Weiner; Leon J Thal; Ronald C Petersen; Clifford R Jack; William Jagust; John Q Trojanowski; Arthur W Toga; Laurel Beckett
Journal:  Alzheimers Dement       Date:  2005-07       Impact factor: 21.566

7.  When is mass spectrometry combined with affinity approaches essential? A case study of tyrosine nitration in proteins.

Authors:  Brînduşa-Alina Petre; Martina Ulrich; Mihaela Stumbaum; Bogdan Bernevic; Adrian Moise; Gerd Döring; Michael Przybylski
Journal:  J Am Soc Mass Spectrom       Date:  2012-08-21       Impact factor: 3.109

8.  Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals.

Authors:  Carina Sihlbom; Pia Davidsson; Magnus Sjögren; Lars-Olof Wahlund; Carol L Nilsson
Journal:  Neurochem Res       Date:  2008-02-21       Impact factor: 3.996

9.  CSF Biomarkers for Alzheimer's Disease Diagnosis.

Authors:  A Anoop; Pradeep K Singh; Reeba S Jacob; Samir K Maji
Journal:  Int J Alzheimers Dis       Date:  2010-06-23

10.  Variability analysis of human plasma and cerebral spinal fluid reveals statistical significance of changes in mass spectrometry-based metabolomics data.

Authors:  Bridgit Crews; William R Wikoff; Gary J Patti; Hin-Koon Woo; Ewa Kalisiak; Johanna Heideker; Gary Siuzdak
Journal:  Anal Chem       Date:  2009-10-15       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.